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Abstract  
 
Bacteria living in the gastrointestinal (GI) tract are crucial for human health 
and disease occurrence. Increasing the beneficial intestinal microflora by 
consumption of prebiotics, which are “functional foods”, could be an elegant 
way to limit the number and incidence of disorders and to recover from 
dysbiosis or antibiotic treatments. This review focuses on the short-chain low-
digestible carbohydrates (LDCs) which are metabolized by gut microbiota 
serving as energy source, immune system enhancers or facilitators of mineral 
uptake. Intake of foods containing LDCs can improve the state of health and 
may prevent diseases as for example certain forms of cancer. Given the large 
number of different molecules belonging to LDCs, we focused our attention on 
fructans (inulin, fructo-oligosaccharides: FOS), galacto-oligosaccharides (GOS) 
and resistant starches and their therapeutic and protective applications. 
Evidence is accumulating that LDCs can inhibit bacterial and viral infections by 
modulating host defense responses and by changing the interactions between 
pathogenic and beneficial bacteria. Animal studies and studies on small groups 
of human subjects suggest that LDCs might help to counteract colorectal 
cancer, diabetes and metabolic syndrome. The action mechanisms of LDCs in 
the human body might be broader than originally thought, perhaps also 
including reactive oxygen species (ROS) scavenging and signaling events. 
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 Introduction  
 
Nowadays an increasing number of people try to prevent diseases and 
reach a better health by modifying their eating habits and life style. According 
to the World Health Organization (WHO, 1948) “Health is a state of complete 
physical, mental and social well-being and not merely the absence of disease or 
infirmity”. 
It is well known that the intake of certain foods can improve the state of health 
and might prevent some diseases as for example certain forms of cancer which 
frequently affect the population. In this context we can easily understand the 
importance, not only from a medical but even from a commercial perspective, 
of the so-called "Functional foods" defined as “Natural or processed foods that 
contain known biologically-active compounds which, when dosed in defined 
quantitative and qualitative amounts, provides a clinically proven and 
documented health benefit, and thus, an important source in the prevention, 
management and treatment of chronic diseases of the modern age” 
(Martirosyan, 2011). This review focuses on low-digestible carbohydrates 
(LDCs), which may be used in prevention of many diseases and especially 
colorectal cancer. 
 
Life inside the intestine 
 
The peculiar structural characteristics found in the intestinal tract of all 
mammals and the presence of metabolites that can be used as substrates by 
microorganisms make it a suitable environment for the colonization and the 
development of a diverse microbial flora. So far, approximately 400 different 
  
 
 
 
 
 
 
 
microbial species have been identified (Frank and Pace, 2008) and reported 
from different zones of the intestinal tract from healthy individuals (Fig. 1). 
More specifically, we can assert that the class of Bacilli, Firmicutes and 
Actinobacteria are prevalent in the small intestine and Bacteroidetes as well as 
Lachnospiraceae are typical in the colon (Frank et al., 2007). Furthermore the 
density of microorganisms varies along the entire digestive tract ranging from 
10-1,000 CFU/ml in the stomach to 10-100 billion CFU/g in the large intestine, 
since it constitutes an appropriate habitat for the development of such 
symbionts (Farthing, 2004).  
The intestinal epithelium presents a superimposition of the internal 
muscle tissue surrounded by the mucous membrane which presents 
microvillosities and also a physic-chemically complex mucus layer that 
separates it from the intestinal lumen. This structure enables the creation of 
additional micro-environments suitable for the development of different 
microbial species. Typically, Clostridium, Lactobacillus and Enterococcus were 
observed in the mucus coating and epithelial crypts of the small intestine while 
Bacteroides, Bifidobacterium, Streptococcus, Enterococcus, Clostridium, 
Lactobacillus and Ruminococcus were detected in feces (Sekirov et al., 2010). 
Furthermore, Wang et al. (2010) demonstrated region-specific gene expressions 
in the epithelium of the colon-mucosa and this could be linked to the presence 
of specific microbiota.  
Anaerobic flora is dominated by Bacteroides spp., Bifidobacteria, 
Propionibacteria and Clostridia. Among aerobic and anaerobic bacteria 
Enterobacteria, mainly Escherichia coli, and Enterococci predominate 
(Swidsinski et al., 2005). The intestinal microflora is not homogeneous among 
the population but greatly varies between people. Moreover, within a certain 
individual it is subject to extensive variation during the course of life. The 
central role of the intestinal microflora in health and disease incidence has been 
recently revalued after the renewed interest in their structure and function. The 
gut symbiotic microorganisms are closely related to different aspects of regular 
host physiology, ranging from the introduction, absorption and utilization of 
nutrients to the lifestyle and stress responses. Accordingly, many diseases, 
which are not necessarily located at the intestinal level, can be triggered or 
influenced by a disturbed gut microflora since this equilibrium can be easily 
modified by many factors (e.g. diet, climate, aging, use of medication, illness 
and lifestyle) (Correia and Nicoli, 2006). The flexible character of the intestinal 
microflora, due to their continuous activity and proliferation, is an essential 
feature allowing them to act as a natural barrier not only capable of performing 
structural and metabolic functions, but also able to protect the intestinal wall. 
Their overall functionality can be summarized into three major tasks which are 
colonization resistance to pathogens; modulation of gastrointestinal and 
systemic immune responses and nutritional support (Olmstead et al., 2008).  
Through the production of short-chain fatty acids (SCFAs), resident 
bacteria provide energy and nutrients for their growth, absorbable substrates for 
the host and positively influence the cell cycle of intestinal epithelium as well 
as other metabolic effects (Shanahan, 2002).  
In healthy individuals microbiota can fulfill direct defensive functions 
through the direct impediment of the colonization by pathogens competing for 
  
 
 
 
 
 
 
 
space and nutrients or indirectly by the production of antimicrobial compounds, 
volatile fatty acids, and chemically modified bile acids. In this way, through the 
colonization resistance or barrier effect, the indigenous gut bacteria are able to 
establish adverse conditions for the inoculation and/or development of the 
enteric pathogens (Roderick et al., 1999).  
In general, if there is a prevalence of gram-positive bacteria Lactobacilli 
and Bifidobacteria in the gut, a condition termed eubiosis is established. This 
term indicates a condition of equilibrium between the host and all the intestinal 
microbial population, instead a disordered state in these symbiotic gut 
inhabitants is known as dysbiosis. 
 
Prebiotics: Gut Microflora “energizing molecules” 
 
A well-known strategy allows sustaining the activity of intestinal 
microflora by the regular intake of beneficial probiotic organisms. Another 
approach is to utilize “prebiotics” to stimulate beneficial bacteria to restore 
from dysbiosis or antibiotic treatments. In contrast to the probiotic strategy 
which provides living microorganisms, the prebiotic application is able to 
stimulate the life cycle and/or increase the metabolic activity of healthful 
bacteria that are already inhabitants of the intestine. For that reason, prebiotics 
are considered simpler and more effective modulators of the gut microflora 
compared to probiotics. 
In the ‘50s György et al. (1953-1954) reported that the consumption of 
substances associated with the diet had positive effects on health by acting on 
the growth and development of Bifidobacteria (known as Lactobacillus bifidus 
at that time) and therefore he termed this the bifidus factor. Later in the ’70s and 
’80s similar studies on the use of digestion-resistant saccharides like fructo-
oligosaccharides (FOS), galacto-oligosaccharides (GOS) and lactulose were 
undertaken by Japanese researchers. Also in this case the results indicated that 
these compounds had a beneficial effect on the intestinal microflora (Yazawa et 
al., 1978) and some of these products came on the market in the ’80s and ’90s. 
Only in 1995, Gibson and Roberfroid gave, for the first time, an exhaustive 
description of prebiotics and their functionalities. Recently prebiotics have been 
redefined as selectively fermented dietary components permitting precise 
variations in the composition and/or activity of the gastrointestinal microflora 
and beneficial for the host health (Roberfroid, 2007a). 
Prebiotics are “functional foods” and in compliance with the European 
Consensus on ‘Scientific Concepts of Functional Foods: “A food can be 
regarded as functional if it is satisfactorily demonstrated to affect beneficially 
one or more target functions in the body, beyond adequate nutritional effects, in 
a way that is relevant to either improved stage of health and well-being and/or 
reduction of risk of disease” (Diplock et al., 1999).  
Furthermore a food can be considered as functional only if it performs 
health benefits in doses which can be normally consumed in a diet and as a 
normal form. Therefore, pills and capsules cannot be considered as functional 
foods. 
  
 
 
 
 
 
 
 
Low-digestible carbohydrates (LDCs), are not (or minimally) digested in 
the stomach or small intestine and are carried on into the large intestine where 
they are fermented by gut microbiota (Scheppach et al., 2001; Holzapfel and 
Schillinger, 2002; Grabitske and Slavin, 2008). Some of the metabolites 
produced in this way can be used as energy source, immune system enhancers, 
facilitators of mineral uptake, etc. (Holzapfel and Schillinger, 2002). LDCs 
selectively stimulate beneficial bacterial groups residing in the colon such as 
Bifidobacteria, Lactobacilli and Eubacteria species (Livesey, 2001; Holzapfel 
and Schillinger, 2002). In addition, LDCs may constrain colonization of 
pathogenic bacteria such as Clostridium and Bacteroides (Holzapfel and 
Schillinger, 2002). Additional benefits associated with LDC consumption may 
include prevention of diseases such as: 
• Type II diabetes (by regulating levels of plasma glucose, insulin 
secretion and insulin sensitivity) 
• Coronary heart disease (by modulating plasma lipid concentration) 
• Gastrointestinal diseases such as colon cancer (by colon acidification, 
stool bulking, protection from pathogen colonization and modulation of 
bacterial microflora) 
• Dental cavities (inhibition of oral acidification) 
• Obesity (low energy value and promotion of satiety) 
Although there are numerous potential benefits associated with 
consumption of LDCs, some dose-related undesirable effects may also occur. 
Unwanted symptoms are usually linked to excessive fermentation and/or 
osmotic effect of prebiotics, including e.g. excessive flatus, bloating, abdominal 
cramps, loss of appetite, sweating, thirst and diarrhea (Livesey, 2001; Marteau 
and Flourié, 2001; Holzapfel and Schillinger, 2002; Grabitske and Slavin, 
2009). Severity of symptoms is highly dependent on the administrated dosage 
(Marteau and Flourié, 2001; Grabitske and Slavin, 2009). Tolerance of LDCs is 
influenced by many factors from which ones mentioned below are the most 
important:  
• Gender – in woman LDCs are usually retained in the upper 
gastrointestinal tract which may cause symptoms as nausea and to a 
slighter extent laxation (Buemann et al., 1999)  
• Age – due to the immature gastrointestinal tract in infants and 
adolescent children diarrhea is up to six time more common than in 
adults (Payne et al., 1997)  
• Molecular weight – LDCs exert an osmotic effect in the intestinal lumen 
which is negatively related to their molecular weight. The increase of 
water flow rate may induce borborygmi, abdominal pain, and diarrhea; 
especially if the capacity of the colon to absorb water and electrolytes is 
exceeded (Marteau and Flourié, 2001) 
• Composition of colonic flora - regular consumption of LDCs results in 
changes in the metabolic activity of the colonic flora and increases its 
fermenting ability. Fewer diarrheas might be expected when LDCs are 
consumed regularly (Florent et al., 1985; Marteau and Flourié, 2001) 
  
 
 
 
 
 
 
 
• Gastrointestinal motility and transit time – LDCs which are not 
fermented are excreted, triggering an increase of bulk and stools water 
content. If transit time or GI motility is too poor for the intestinal cells 
to absorb the excess water, this may induce diarrhea (Grabitske and 
Slavin, 2008). 
 
Clinical research studies reported on the toleration doses for various LDCs. 
Non-starch carbohydrates like guar gum, inulin, and FOS are in general well-
tolerated at intake levels up to 15 g/day (Grabitske and Slavin, 2009). 
Polydextrose is tolerated at much higher doses of maximum 50 g/day (Flood et 
al., 2004) and resistant starch is well-tolerated at doses not exceeding 45 g/day 
(Van den Heuvel et al., 2004; Robertson et al., 2005). Assessed acceptable 
intake of sugar alcohols ranges from 20 g/day to 40 g/day (Rushton and Slavin, 
2007). Since dose-related intolerance symptoms may occur during the 
treatment, it is important to adjust the therapeutic dose to each individual 
patient. The therapeutic window is frequently wide-ranging and preeminent 
benefits can be obtained with accurate dosage (Delzenne, 2003). 
 
Fructans, substances with a proven prebiotic effect 
 
Fructans are a group of non-structural carbohydrates occurring in 15% of 
the flowering plant species and in some bacteria, algae and mosses (Hendry and 
Wallace, 1993). The identification of the first fructan has occurred in the 1804 
by a German scientist who found “a peculiar substance from plant origin in a 
boiling water extract from Inula helenium". A few years later, in 1818, another 
researcher, Thompson, identified this substance as inulin. 
Inulin-type fructans are synthesized and stored in vacuoles of Asteracean 
plants. Particular species belonging to this family play an important economic 
and nutritional role such as chicory (Cichorium intybus) Jerusalem artichoke 
(Helianthus tuberosus) (Carabin and Flamm, 1999) and artichoke (Cynara) 
accessions (Raccuia and Melilli, 2010).  
Fructans are polymers of fructose that often contain a terminal glucose 
moiety. They can have a linear or branched structure. For simplicity, a 
subdivision into five main groups can be made on the basis of the position of 
glucose moieties (internal or end position) and on the glycosidic linkages 
between their fructosyl residues (Fig. 2). Inulin-type fructans consist of fructose 
units linked through β-2,1 bonds and displaying a linear structure. 1-kestotriose 
(1-kestose) is the simplest inulin-type fructan produced by the activity of a 
sucrose:sucrose 1-fructosyl transferase (1-SST) which transfers a fructosyl 
residue from donor to an acceptor sucrose, producing 1-kestotriose. 
Fructan:fructan 1-fructosyl transferase (1-FFT) further polymerizes 1-
kestotriose into higher DP inulin-type fructans (Fig. 2). Sucrose:fructan 6-
fructosyl transferase (6-SFT) preferentially transfers a fructosyl group from 
sucrose as a donor substrate to 1-kestotriose as acceptor substrate, producing 
1&6-kestotetraose (also termed bifurcose), the smallest graminan-type of 
fructan with mixed type of linkages (Fig. 2). Bifurcose can be further elongated 
by 6-SFT and 1-FFT, leading to branched, higher DP graminans.  The levan-
  
 
 
 
 
 
 
 
type fructans consist of β-2,6 fructosyl–fructose bonds. They are linear and 6-
kestotriose (6-kestose) is the shortest fructan of the levan-type. Levan synthesis 
is believed to occur by a sucrose:fructan 6-fructosyl transferase with intrinsic 
sucrose:sucrose 6-fructosyl transferase characteristics (a 6-SST/6-SFT). Finally, 
the enzyme fructan:fructan 6G-fructosyl transferase (6G-FFT) synthesizes 6G-
kestotriose (6G-kestose, neokestose) from 1-kestotriose as donor substrate and 
sucrose as acceptor substrate. Further elongation by 1-FFT and 6-SFT leads to 
the formation of inulin neoseries and levan neoseries, respectively (Van den 
Ende et al., 2002; Lasseur et al., 2006; Tamura et al., 2009). 
A common way to denote, in an abbreviated form, the structure of 
fructans is indicating the glucose units with G and the number of fructose units 
with Fn. The first monomer that starts the fructan chain may be a β-D-
glucopyranosyl, as in GpyFn [glucopyranosyl-(fructofuransoyl) n-fructose] or a 
β-D-fructopyranosyl residue as for example in FpyFn [fructopyranosyl-
(fructofuranosyl) n-fructose] (Vester-Boler and Fahey, 2012). 
 
Oligosaccharides and microbiota 
 
Oligosaccharides are low molecular weight carbohydrates with a degree 
of polymerization (DP) ranging between 2 and 9. They are easily soluble in 
water and their typical sweetness decreases with their increasing chain length. 
On the contrary, their water-binding and gelling properties, which make them 
putative fat substitutes, increase with the number of hexose molecules. The 
principal sources of these substances are chicory, asparagus, artichoke, onions, 
garlic, leeks and soya beans as well as in human breast milk and cow's milk 
(Conway, 2001). The pivotal characteristic of oligosaccharides, once eaten, is 
their resistance to be metabolized by hydrolytic enzymes as α-glucosidase, 
maltase and isomaltase secreted into or active in the intestine. The digestive 
capacity of these enzymes towards β-2,1 fructans (inulins) is ineffective. 
Digestibility can also greatly depend on their DP. For instance, isomalto-
oligosaccharides with a DP > 3 cannot be properly digested (Delzenne, 2003).  
Oligosaccharides, which mostly escape digestion in the upper 
gastrointestinal tract, are important sources of energy for bacteria in the caeco-
colon that express enzymes such as β-fructosidase, β-galactosidase, xylanase or 
other hydrolases (Bernalier et al., 1999). The glycosidic bonds arrive in the 
colon almost intact (with the exception of some slight hydrolysis in the 
stomach) because of their resistance to enzymatic hydrolysis in the previous 
part of the intestine. The process of fermentation operated by colonic microbes 
on LDCs generates SCFAs as main products and also gases such as carbon 
dioxide, methane and hydrogen. An important outcome is the pattern of 
fermentation, i.e. the proportion of the different SCFAs acetate, propionate, 
butyrate and lactate, produced in the caecum varies with the nature of the 
oligosaccharides, at least in animals. The ratio between the level of acetate and 
propionate is six-times higher in the caecum of rats fed with a diet based on 
GOS compared with a control population whose diet contained the same 
quantity of FOS (Sakaguchi et al., 1998). The proportion also changes with the 
duration of the treatment; for example a study showed that in rats, whose diet 
was enriched in FOS, a temporal increase in lactate and a constant increase in 
  
 
 
 
 
 
 
 
butyrate was observed after 27 weeks (Le Blay et al., 1999). A diet rich in FOS 
also led to elevated sulfomucins in the caeco-colonic mucosa of rats. These 
compounds are known for their protective activity (Cherbut, 2002). The SCFAs 
generate important effects in the intestinal tract. It is broadly accepted that 
butyrate fulfills an important function in maintaining the metabolism, 
proliferation and differentiation of the different epithelial cell types (Blottiére et 
al., 1999). Unfortunately, since there is not a direct correspondence between the 
real production of SCFAs in the colon and the quantity excreted in the feces, it 
is not easy to have a clear idea of the effects of prebiotics on the production of 
SCFAs in humans. 
As claimed before, prebiotics can selectively stimulate the growth and/or 
the activity of selected intestinal bacteria causing changes in the overall 
microbial population which are health promoting for the host (Gibson, 2008). Is 
not clear yet which specific mechanisms are implicated in the metabolism of 
prebiotics, although there are two general models that can partially explain this 
process. The most accepted model is based on the action of cell-associated exo-
glycosidases by probiotic microorganisms (Perrin et al., 2001). Such enzymes 
act by cleavage of monosaccharides from the non-reducing end of the 
oligosaccharides, which are then taken up within gut epithelial cells. 
Furthermore, Kaplan and Hutkins (2000) and Gopal et al. (2001) assert that 
probiotic microorganisms can perform intracellular metabolism after absorption 
of the oligosaccharides.  
Most of the initial studies on colonic microbiota have focused exclusively 
on Bifidobacteria species present in the fecal material. However, increasing 
evidence suggests that the epithelial surface is populated by large and diverse 
bacterial communities, which are completely different from those occurring in 
the lumen of the intestine (Macfarlane et al., 2004). Such bacteria are able to 
grow in bio-films in the vicinity of the colonic mucosa and they are considered 
important modulators of immune responses (Neish et al., 2000).  
A mixture of compounds with specific protective functions, such as the 
mucins (MUC1, 2, 3, and 4) and trefoil factors (TFF 1, 2, and 3) are present in 
the mucus bio-film adjacent to the colon. Feeding studies on rats with FOS and 
resistant starch showed MUC2 increases in the colon, but the effect was 
superior upon combining both substances (Rodriguez-Cabezas et al., 2010). 
Other studies report increased levels of Lactobacilli associated with prebiotic 
consumption. A significant dose-related increment in fecal Lactobacilli was 
observed in subjects consuming GOS for 7 days (Ito et al., 1990). Nevertheless 
it is critical to take into account the pre-treatment levels of these 
microorganisms. For example, if there are already high levels of Bifidobacteria, 
it is difficult to show an eventual elevation following the administration of one 
or more prebiotic(s) (Roberfroid et al., 1998). 
Currently, the most studied and known prebiotics are GOS, lactulose, 
inulins and FOS, which can be produced either by extraction from plants or as 
products of enzymatic activity. Several studies conducted both on animals and 
on humans (Bouhnik et al., 2004; Gibson et al., 2004; Roberfroid et al., 2010) 
have confirmed the hypothesis that only limited daily amounts of these 
substances are needed, ranging from 5 to 20 g, to achieve real beneficial effects 
  
 
 
 
 
 
 
 
on intestinal microbial populations. It has been demonstrated that symbiotic 
bacteria, once they get in contact with the prebiotic molecules, are able to 
metabolize them directly (Ohtsuka et al., 1989). Alternatively, their growth can 
be indirectly influenced by molecules such as lactate, which are intermediate 
products from other fermentations leading to a process called cross-feeding 
(Belenguer et al., 2006; De Vuyst and Leroy, 2011). 
Additional molecules which have been recently classified as prebiotics 
are lactitol, mannitol, maltodextrin, raffinose, lactulose, sorbitol, 
isomaltooligosaccharides (IMO), mannan-oligosaccharides (MOS) and 
xylooligosaccharides (XOS). Also wheat bran-derived 
arabinoxylooligosaccharides (AXOS) are putative promising prebiotics 
(Sabater-Molina et al., 2009; Femia et al., 2010; Vamanu and Vamanu, 2010; 
Yeo and Liong, 2010; Broekaert et al., 2011; Corrigan et al., 2011).  
 
Inulin, FOS and GOS  
 
Inulin-type fructans are the most studied and widely applied prebiotics. 
Inulin molecules with a degree of polymerization ranging from 2 to ≥60 are 
commercially available (Roberfroid, 2007b) and acknowledged as stimulators 
of SCFAs in the colon, favoring the growth of Lactobacilli and Bifidobacteria, 
associated with reduced mucosal inflammation and lesion scores in a rat model 
of inflammatory bowel disease (IBD) (Videla et al., 2001). The β-configuration 
of their bonds makes inulin-type fructans resistant to digestive enzymes present 
in saliva and intestine which are only able to cleave α-glycosidic bonds types. 
Inulins and FOS are degraded in the colon by anaerobic bacteria, however, 
some limited non-enzymatic acid hydrolysis in the stomach cannot be excluded. 
The most common dietary sources are wheat, onion, artichoke, garlic and leek. 
The average intake of inulin has a large variability and is between 3 and 11 g 
per day in Europe (Van Loo et al., 1995). For comparison, the intake in the 
United States is significantly lower, with a daily consumption average between 
1 and 4 g (Moshfegh et al., 1999).  
The plant that is most commonly used for the industrial extraction of 
inulin-type fructans belongs to the Asteraceae (Compositae) family, i.e., 
chicory (Cichorium intybus L.). The native chicory inulin extracted from fresh 
roots is non-fractionated (De Leenheer, 1996) and to obtain a more effective 
product, purification procedures and removal of ions are necessary. By applying 
an endo-inulinase of microbial origin it is possible to obtain, starting from 
inulin, oligofructose molecules also known as fructooligosaccharides (FOS). 
FOS are a mixture of GpyFn and FpyFn such as 1-kestotriose, 1,1-kestotetraose 
and 1,1,1-kestopentaose as well as inulobiose, inulotriose, and inulotetraose all 
characterized by low DP values ranging between 2 and 7 (Roberfroid, 2007b). 
FOS might also be produced by the enzymatic process of transfructosylation 
exerted by a β-fructosidase of Aspergillus niger with sucrose as substrate 
(Shoaf et al., 2006). Because of the lower amount of kilocalories found in FOS 
(1 kcal/g) compared to sucrose (4 kcal/g) (Roberfroid et al., 1998) and their 
higher solubility as compared to inulins, FOS are sometimes used in 
combination with artificial sweeteners or directly as food additives in yogurt 
  
 
 
 
 
 
 
 
and derivatives. The use of 8 g of oligofructose per day in 20 healthy subjects 
has been shown to promote satiety and reduced food intake (Cani et al., 2006).  
Another important class of prebiotic molecules are the GOS which are 
mainly obtained by the action of the enzyme β-galactosidase on lactose, 
resulting in the production of 4’- or 6’-galactosyllactose, longer 
oligosaccharides, trans-galactosylated disaccharides and non-reducing 
oligosaccharides consisting of lactose molecules with one or more galactosyl 
residues linked by β-1,3, β-1,4 and β-1,6 bonds. This variability in glycosidic 
linkages may be one of the reasons why GOS possess increased resistance to 
acid digestion (Tomomatsu, 1994). Since birth, the human body gets 
accustomed to regular intake of GOS. Breast milk provides a variety of GOS 
based on the lactose, next to the lactose itself (ESPGAN, 1977). 
GOS are stable at high temperatures in rather acidic environments and 
the calorific value of these oligosaccharides is approximately 1 to 7 kcal/g, and 
therefore they are particularly useful for food applications. They are popular as 
prebiotics and sweeteners in confectionary, in acidic beverages and in 
fermented milks. It is validated that the consumption of GOS, like FOS, leads to 
significant health benefits. For instance, mice infected with Salmonella enterica 
serotype Typhimurium appear to be protected and able to resist the infection 
when fed with GOS, also enhancing the growth and activity of Bifidobacterium 
breve (Shimizu et al., 2001). Recent in vitro studies showed that a number of 
these substances have the potential to mimic eukaryotic cell surface receptors 
that are an active part during the pathogenicity process as anchor site for 
virulent bacteria. For example, GOS was reported to be more efficient than 
either inulin or FOS in the inhibition of the tight adhesion of EPEC 
(enteropathogenic Escherichia coli) to HEp-2 and Caco-2 cells (Shoaf et al., 
2006). 
 
Resistant starch 
 
Resistant starch (RS) is defined as "The sum of the starch and products of 
starch degradation not absorbed in the small intestine of healthy individuals" 
(EURESTA, 1991).  
Starch consists of two main components, amylose and amylopectin. Most 
starches contain mainly amylopectin (often 70-80%) which is an extremely 
large glucose polymer (10,000-100,000 monomers units) containing α-1,6 
branch points. The remaining fraction consists of amylose, a linear polymer 
(100-10,000 monomer units) of α-1,4 linkages which is mainly found in the 
amorphous regions of starch granules (Conway, 2001). The starch taken with 
the diet is not always digested in the upper GI tract. In fact, a large amount is 
subjected to the process of fermentation in the large intestine (Annison and 
Topping, 1994; Gibson et al., 2004; Fuentes-Zaragoza et al., 2011). The reason 
for this resistance may be linked to the structural characteristics of the starch 
granules making them rather inaccessible to the intestinal microflora of the 
upper part of the gut, besides other factors such as degree of retrogradation after 
cooking. 
Classic plant breeding selection programs led to the production of starch 
enriched in amylose (80%). This form of high amylose starch from maize 
  
 
 
 
 
 
 
 
(amylomaize) was shown to improve the SCFA profiles in humans and also 
functions as a dietary fiber with laxation properties (Noakes et al., 1996; Brown 
et al., 1997; Topping et al., 1997). A regular administration of amylomaize in 
diets of pigs reduced the amount of unhealthy microbes such as Coliforms 
(Vaidya and Sheth, 2010). In addition, to prove the effectiveness of these 
compounds as prebiotics, a screening was performed of more than 40 
inhabitants of the human colon. It was demonstrated that only Bifidobacterium 
spp. are capable to use these starch granules as the sole carbon source (Brown 
et al., 1998). Further studies in mice showed an increase in the levels of 
Bifidobacterium spp. (<log 2 cfu per gram faeces initially to log 8.3 cfu per g 
feces after four weeks) (Wang et al., 1999a). In some cases it has been shown 
that Bifidobacteria have the feature to use the surface of starch granules, in 
particular amylomaize, as a site of anchoring. The underlying reason for this 
behavior is to ensure their protection. In this way, microorganisms become 
more resistant to pH changes or to excess presence of bile acids. As a 
consequence, bacterial flora has a higher fitness (Palframan et al., 2002). Other 
studies now focus on the activity of chemically modified amylomaize starches. 
The aim of these modifications is to favor the proliferation of Lactobacilli both 
in vitro and in vivo, to adapt these substances to the desired populations in situ 
(Wang et al., 1999b).  
1.1.1.2 Therapeutic use of LDCs 
1.1.1.3 Prevention of bacterial infections 
Among LDCs, FOS occupy a key position by their ability to change 
significantly the composition of the colonic microflora, resulting in modulation 
of host defense and changing interactions between pathogenic and beneficial 
bacteria.  
The gut epithelium is covered by a thick mucus layer that acts as a first 
defense barrier against the microbiota and pathogenic bacteria and is largely 
composed of mucin. The mucus layer contains various digestive enzymes and 
antimicrobial peptides as well as immunoglobulins (Liévin-Le Moal and Servin, 
2006; Dharmani et al., 2009). The production of mucin is also upregulated as a 
response to local acidification by regulation of the secretory function of colonic 
goblet cells (Bertin et al., 2001). Higher amounts of mucin, forming gel-like 
chemical barriers, inhibit colonization and translocation of microbes such as 
Salmonella spp., Shigella spp., Vibrio cholerae, enteropathogenic Escherichia 
coli (EPEC), enterohemorrhagic E. coli (EHEC) and Yersinia (Barcelo et al., 
2000; Bertin et al., 2001). EHEC causes illnesses ranging from mild diarrhea to 
severe diseases such as haemorrhagic colitis and haemolytic uraemic syndrome 
(Fukuda et al., 2011). EHEC (E. coli O157) can produce Shiga toxins (Stx), 
Stx1 and Stx2, which are a crucial factor in lethal infections (Bertin et al., 
2001). Experimental data show that certain Bifidobacteria spp. protect mice 
against death after E. coli infection. This effect can be attributed to increased 
production of acetate and inhibition of translocation of Stx from the gut lumen 
into the bloodstream (Fig. 3A) (Ashida et al., 2011; Fukuda et al., 2011). 
Acetate improves intestinal defense mediated by epithelial cells and thereby 
protects the host against lethal infection. SCFAs (especially acetate) can also 
bind to G protein coupled receptors 41 and 43 on immune cells within the gut-
associated lymphoid tissues (GALT) and regulate inflammatory responses (Fig. 
  
 
 
 
 
 
 
 
3B) (Le Poul et al., 2003; Maslowski et al., 2009; Ashida et al., 2011). It is 
proposed that high levels of SCFAs may, in addition to its direct effects on the 
GPR43 response, affect the biosynthesis of endogenous fatty acids, such as 
resolvins modulating leukocyte functions (Maslowski et al., 2009). Butyrate, 
produced mainly by Fecalibacterium prausnitzii, Eubacterium rectale and 
Roseburia species, is able to induce the expression of the epithelial 
antimicrobial peptide LL37 which is correlated with prevention of bacterial 
infections (Ashida et al., 2011). Moreover, it supplies energy for the colonic 
epithelium and prompts epithelial proliferation as well as injury repair 
(Guilloteau et al., 2010). It has been shown that butyrate can reduce colonic 
inflammation and bacterial loads in the stool triggered by Shigella infection in 
rabbits (Fig. 3C) (Raqib et al., 2006). 
 
 
Furthermore, it is proposed that LDCs may also influence host immune 
function by direct interactions with receptors on immune cells, such as T 
lymphocytes (CD4+ and CD8+) and B lymphocytes (memory cells and 
plasmocytes) present in GALT. It is postulated that -glucan carbohydrate 
moieties can directly bind to the receptor on monocytes/macrophages, 
neutrophil cell lineages, dendritic cells (DC) and at a lower level on a sub-
population of T cells (Herre et al., 2004a; Thompson et al., 2010). Murine 
Dectin-1 receptor and its human homologue hDectin-1 are proposed to be main 
targets for -glucan binding and recognition (Taylor et al., 2002; Herre et al., 
2004a,b; Valera et al., 2008; Thompson et al., 2010). Activation of Dectin-1 
initiates endocytosis and phagocytosis, respiratory burst as well as production 
stimulation of the numerous cytokines and chemokines such as TNF, CXCL2, 
IL-23, IL-6, IL-10, IL-2, and IL-12 (Taylor et al., 2002; Gantner et al., 2003; 
Herre et al., 2004a,b,c; Rogers et al., 2005; Valera et al., 2008; Tsoni and 
Brown, 2008; Thompson et al., 2010). It has been demonstrated that β-glucans 
have the ability to protect against bacterial, viral, fungal, and protozoal 
infection and therefore it is often included as an immune booster in feed 
supplements for farmed animals (Brown and Gordon, 2003; Thompson et al., 
2010). Recently, also the antiviral activity of fructans was suggested (Esawy et 
al., 2011; Lee et al., 2012). As further described in more detail below, both 
fructans and β-glucans show antitumor activity and they contribute to a 
lowering of serum cholesterol and glucose levels. Moreover, β-glucans enhance 
wound repair, influence blood pressure, and support ischemia/reperfusion 
recovery (Tsoni and Brown, 2008).  
SCFAs concentration in different parts of GI tract can directly disturb 
both viability and virulence gene expression of enteric pathogens species as 
Salmonella, Pseudomonas aeruginosa and Enterobacteriaceae (Duncan et al., 
2004; Forchielli and Walker, 2005; Gantois et al., 2006; Huang et al., 2008; 
Ashida et al., 2011). Differences in concentrations and locations of two 
particular SCFAs, which are formate and butyrate, induce changes in the 
intestine environment and can alter virulence characteristics of pathogens like 
Salmonella (Levison, 1973; Cummings et al., 1987; Laerke et al., 2000; 
Duncan et al., 2004; Forchielli and Walker, 2005; Gantois et al., 2006; Huang 
et al., 2008; Ashida et al., 2011). For instance, formate is usually present in the 
  
 
 
 
 
 
 
 
small intestine in low concentrations and is undetectable in the cecum (Gantois 
et al., 2006). In contrast, butyrate is present in the cecum but is not detectable in 
the small intestine (Gantois et al., 2006). 
The ability of countless pathogenic microorganisms to adhere to the 
mucosal surface is crucial for their distribution in the intestine (e.g. Escherichia 
coli, Helicobacter jejuni, Shigella strains, Vibrio cholerae) (Argenzio et al., 
1974; Miller and McVeagh, 1999; Shoaf et al., 2006; Ashida et al., 2011). 
Ligand-receptor interactions between bacterial components and the mucosal 
surface of the host are essential in the adhesion process. Oligosaccharides and 
glycoproteins present in large amounts and great variety in the mammals gut 
can protect from adhesion of microorganisms through their ability to act as 
receptor analogues (Miller and McVeagh, 1999; Shoaf et al., 2006). For 
example, GOS present in milk and lactulose are capable to constrain adherence 
of Campylobacter jejuni, E. coli, Helicobacter pylori, and other pathogens 
(Miller and McVeagh, 1999; Newburg, 1999; Kunz et al., 2000; Morrow et al., 
2005; Shoaf et al., 2006). The structures of LDCs are highly associated to their 
function as it was reported that FOS, inulin, xylo-oligosaccharides (XOS) and 
their mixtures induce greater inhibition of pathogens than lactulose, lactitol, 
starch and dextran (Fooks and Gibson, 2002; Ebersbach et al., 2012). 
Furthermore, structural features, such the type of bond and DP affect the 
fermentation rate, defining the release rate of inhibitory metabolic end products 
(Fooks and Gibson, 2002). 
 
Cancer prevention 
 
Colorectal cancer represents a major public health problem causing every 
year over a half million deaths worldwide (Chau and Cunningham, 2006; 
WHO, 2012). Treatment highly depends on the stage of the cancer and may 
include surgery (colectomy), chemotherapy or radiation therapy. Treatment 
success rates vary for local recurrence, disease-free survival, and overall 
survival (WHO, 2012). These treatments often present effects such as an 
increased risk for infections, hair loss, fatigue, vomiting, diarrhea etc. Although 
threat of colon cancer is upregulated by the genetic factors such as familial 
polyposis and ulcerative colitis, the main factors include environmental causes 
such as exposure to carcinogens and dietary composition (Cassidy et al., 1994; 
Brady et al., 2000; Bruce et al., 2000; Chau and Cunningham, 2006; Ryan-
HarshmanAldoori, 2007). 
Consumption of fiber and resistant starches is well-thought-out as the 
protective step in prevention of colon cancer (Cassidy et al., 1994; Chau and 
Cunningham, 2006; Ryan-Harshman and Aldoori, 2007). Many studies suggest 
that prebiotics counteract colon carcinogenesis by the production of SCFAs, 
mainly acetate, propionate and butyrate (Fig. 4) (Topping and Clifton, 2001; 
Chau and Cunningham, 2006; Liong, 2008). Prebiotics can also modify gene-
expression in tumor cells or decrease activity of cancer triggering bacteria 
(Lorraine et al., 2003). 
 
  
 
 
 
 
 
 
 
 Dietary carbohydrates recognized in prevention of colon cancer include 
-glucans, dietary fibers, fructans and resistant starch (Cassidy et al., 1994; 
Bruce et al., 2000; Ryan-Harshman and Aldoori, 2007). 
Dietary fibers and -glucans increase viscosity and bulking in the colon, 
influencing absorption of minerals, triglycerides and boosting intestinal transit 
(Scheppach et al., 2001; Lorraine et al., 2003; Ryan-Harshman and Aldoori, 
2007; Grabitske and Slavin, 2008; Liong, 2008). The presence of LDCs in the 
gut causes a “diluting” effect, reducing the interaction time of potential 
mutagens and carcinogens with colonic epithelial cells. Furthermore, SCFAs 
produced through fermentation of LDCs by colonic bacteria decrease the 
colonic pH, resulting in the growth of beneficial bacteria and depletion of 
harmful and pathogenic species (Gibson and Wang, 1994; Blaut, 2002; Lorraine 
et al., 2003; Fukuda et al., 2011). For instance it is well established that 
Clostridium and Coliform infections are associated with the malignancies of the 
ascending colon (Schaaf et al., 1980; Larson et al., 1995). Furthermore, the 
decrease in pH also increases mineral solubility and uptake, specifically 
calcium, magnesium and iron. Enhanced calcium absorption in the gut restricts 
calcium depletion from the bones (Lipkin and Newmark, 1995; Lamprecht and 
Lipkin, 2003; Lim et al., 2005). Resistant starches such as high amylose corn 
starch are highly viscous with properties comparable to a soluble fiber. Their 
fermentation produces high levels of butyrate which functions at the level of 
gene expression, inhibiting malignant transformation by reducing proliferation, 
and inducing differentiation and cell apoptosis (Bingham, 1990; Kruh et al., 
1994; Hague and Paraskeva, 1995; Lorraine et al., 2003). Furthermore, butyrate 
stimulates the synthesis of proteins such as alkaline phosphatase, glycoproteins, 
hormone receptors and ion-binding metallothioneins (Scheppach et al., 2001) 
which may aim to re-establish normal characteristics in developing tumor cells. 
Evidence exists that butyrate inhibits proliferation of colon cancer cells, 
initiating an arrest at the early G1 phase due to its action on the gene expression 
involved in the control of the cell cycle, bearing oncogenes (Toscani et al., 
1988; Scheppach et al., 2001).  
Inulin-type fructans are well studied in terms of cancer prevention. 
Significant anticarcinogenic properties have been found in animal studies. 
Inulin reduced tumor incidence and formation of aberrant crypt foci, initiated 
by carcinogenic compounds such as azoxymethane (AOM) and 
dimethylhydrazine (DMH) (Hidaka et al., 1990; Rowland et al., 1998; Pool-
Zobel, 2005). Those effects are possibly produced by stimulation of 
Bifidobacteria, which themselves have been shown to act as antigenotoxic in 
the colon and to reduce AOM-induced tumors.  
Protective effects of LDCs rise with increasing structural complexity 
(DP and branching). For instance, inulin, long-chain inulin and a mixture of 
short- and long-chain inulin compounds showed a more extended protective 
effect than oligofructose (Pool-Zobel et al., 2002). This could be attributed to 
the lower fermentation rate of inulin compared to oligofructose, being able to 
reach the distal parts of the colon. Inulin-type fructans are known to induce 
apoptosis of colonic cells with mutations in their DNA. Similarly, elimination 
of carcinogenic colonic cells by inulin is more effective than oligofructose, 
again pointing to the importance of structural differences (Hughes and 
  
 
 
 
 
 
 
 
Rowland, 2001). Inulin-type fructans are fermented extensively by large bowel 
microflora to lactic acid and SCFAs (Hidaka et al., 1990; Pool-Zobel et al., 
2002) contributing to the protective effects and apoptosis induction. 
Permeability of inulin has been measured in normal, adenomatous, 
colitic and malignant large bowel epithelial cells showing that all carcinomas 
displayed its extensive uptake. Accumulation of inulin by carcinomas could not 
only be attributed to pinocytosis (Chambers and Serafini, 1985) since only 
partial inhibition was observed with cytochalasin B, a well- known inhibitor of 
pinocytosis and phagocytosis (Von Figura and Kresse, 1974). These data 
suggested the existence of alternative uptake mechanisms besides pinocytosis 
(North, 1983). Compared to carcinomas, normal, adenomatous and colitic 
epithelial seem to have a more limited permeability to inulin, which is 
correlated with its molecular weight and hydrodynamic radius (Ghandehari et 
al., 1997). This suggested that membrane properties, vastly depending on their 
lipid and protein composition, may be an important factor explaining the 
extended inulin uptake in carcinogenic cells. The increased membrane fluidity 
of cancer cells is associated with metastasis (Nakazawa and Iwaizumi, 1989; 
Sok et al., 2002; Wang, 2005) and often specific characteristics are observed 
such as the inability to synthesize some types of lipids (as for example 
glycolipids), or the deletion of terminal saccharide residues in glycolipids 
(Wang, 2005). Increase in ion permeability can induce extensive proliferation 
and compromised reception of differentiation directing signals from 
neighboring cell due to closure of gap junctions (Chambers and Serafini, 1985). 
It is postulated that inulin accumulation can slow down tumor proliferation and 
induce apoptosis (Munjal et al., 2009; Chung et al., 2011) although further 
studies are necessary to unravel the precise action mechanism. 
The role of reactive oxygen species (ROS) in carcinogenesis has been 
extensively investigated during the last decade. ROS play an important role in 
the modulation of several physiologic responses as induction of programmed 
cell death or necrosis, induction or suppression of genes expression, activation 
of cell signaling cascades and induction or inhibition of cell proliferation 
(Hancock et al., 2001; Gibellini et al., 2010). ROS, if produced in an 
uncontrolled manner, induce cellular damage and can give rise to pathological 
conditions. One of the key features of the cancer cells is a tenacious pro-
oxidative state leading to oxidative stress (Szatrowski and Nathan, 1991; 
Toyokuni et al., 1995; Gibellini et al., 2010). ROS are continuously created in 
cancer cells as a result of several factors, including increased metabolic activity, 
the activation of oncogenes, and the eventual loss of tumor suppressor protein 
p53 (Pelicano et al., 2004; Gibellini et al., 2010). 
Flavonoids -compounds naturally occurring in a great variety of foods 
and beverages- are believed to counteract carcinogenesis, mainly due to their 
antioxidant properties (Gibellini et al., 2010). They have also the ability to 
modify proteins involved in cell proliferation and cell death pathways (Gibellini 
et al., 2010). Quercetin (Qu) is an important dietary flavonoid, present in 
different vegetables, fruits, seeds, nuts, tea, and red wine. Quercetin can affect 
ROS metabolism and induce cell apoptosis (Gibellini et al., 2010). When 
cancer cells, containing high levels of ROS, are exposed to quercetin, toxic 
oxidation products are formed (quercetin-semiquinones and quercetin-quinones; 
  
 
 
 
 
 
 
 
Fig. 5) (Metodiewa et al., 1999; Gibellini et al., 2010). Those chemicals exert 
pro-oxidant properties and are highly reactive towards thiols and easily react 
with reduced glutathione (GSH) initiating its depletion. In normal cells exposed 
to ROS, as for instance H2O2, GSH biosynthetic pathways are stimulated to 
counteract the oxidative stress (Ferraresi et al., 2005; Gibellini et al., 2010). 
ROS increases play an important role in the manifestation and conservation of 
the cancer phenotype, leading to a pro-oxidative state. ROS induce 
chromosomal instability through accumulation of mutations and deletions in the 
genetic material and stimulates cell growth and proliferation, as well as cell 
migration and invasiveness (angiogenesis and metastasis). The adaptation of 
cancer cells to high levels of ROS involves modification of the antioxidant 
functions and upregulation of pro-survival proteins which allows them to 
escape apoptosis (Fig. 5) (Gibellini et al., 2010). 
Quercetin triggers GSH depletion, eliciting apoptosis via mitochondrial 
depolarization (Ferraresi et al., 2005; Lugli et al., 2005; Ly et al., 2003; Choi et 
al., 2005; Troiano et al., 2007; Gibellini et al., 2010). Moreover, when levels of 
GSH are highly reduced, products of mitochondrial pathways such as H2O2 can 
damage the organelle through loss of mitochondrial membrane potential and 
release of cytochrome c into the cytosol (Fig. 6). Finally activation of caspases 
occurs, such as caspase-3 and caspase-7, and apoptosis takes place (Kuo et al., 
2004; Choi et al., 2005; Yang et al., 2006; Chien et al., 2009; Chou et al., 2010; 
Niue et al., 2011). 
Quercetin can also modulate pro-apoptotic and antiapoptotic proteins 
such as Bax, Bak, Bcl-2 and Bcl-xL (Kuo et al., 2004; Yang et al., 2006; Chien 
et al., 2009; Niu et al., 2011) and the PI3K/Akt pathway, which are important in 
cell survival and proliferation (Yang et al., 2006; Gibellini et al., 2010).  
Further studies are needed on the exact uptake mechanisms of 
flavonoids and prebiotics, on the exact concentrations of these compounds in 
epithelial cells and on the interactions between these compounds, ROS and 
cellular proteins. It can be speculated that these compounds act as direct ROS 
scavengers (Bolouri-Moghaddam et al., 2010; Van den Ende et al., 2011). 
Alternatively, and perhaps more likely, they can interfere with the uptake 
mechanisms of glucose or other metabolites and/or with AMPK signaling 
pathways (De Gara et al., 2003; Yun et al., 2009; Stoyanova et al., 2011). In 
particular, the antioxidant effect of levan-type fructans under oxidative stress 
conditions was examined on pancreatic INS-1E cells. Under high glucose 
condition, oxidative stress and apoptosis were significantly increased in cells 
treated with hydrogen peroxide. However, treatment with levan decreased 
oxidative stress and attenuated apoptosis (Kazak et al., 2011). 
 
Diabetes and metabolic syndrome prevention 
 
Metabolic syndrome is a collection of conditions that as a group increases 
the risk of developing cardiovascular disease and type 2 diabetes mellitus. 
These disorders include high blood pressure, high sugar and triglycerides levels. 
Central obesity and insulin resistance are recognized as significant activating 
factors. Other causes include physical inactivity, ageing and hormonal 
  
 
 
 
 
 
 
 
imbalance caused by polycystic ovary syndrome (PCOS) or testosterone 
insufficiency (Anderson et al., 2001; Gustat et al., 2002; Cho, 2011). 
Diabetes mellitus is typically characterized by high blood glucose levels, 
resulting from defects in insulin secretion or insulin insensitivity. Diabetes is a 
chronic medical illness that can produce coronary artery disease, 
cerebrovascular disease, renal failure, limb amputation, blindness, neurological 
complications and premature death (Weidmann et al., 1993; Gobinath et al., 
2010).  
In animal model studies, dietary supplementation of 10% XOS and FOS 
were able to improve body weight in diabetic rats, reduced mortality and 
significantly increased the Bifidobacteria and Lactobacilli population in the 
caecum (Gobinath et al., 2010). The improved bacterial population induced a 
reduction of the pH in caeca associated with rising SCFA concentrations. 
Lactate, acetate, propionate and butyrate, which are rapidly absorbed from the 
lumen of the colon, can influence glucose levels, lipid metabolism and lower 
cholesterol levels (Venter et al., 1990; Laurent et al., 1995; Al-Lahham et al., 
2010; Gobinath et al., 2010). Acetate passes to peripheral tissues where it is 
metabolized by muscles, adipose tissue or heart tissue (Mayfield et al., 1966). 
Butyrate is largely utilized by the colonocytes and propionate is removed by the 
liver (Cummings et al., 1987; Gobinath et al., 2010) influencing the 
intermediary metabolism in those tissues.  
Further examination of butyric acid metabolic activities in diet-induced 
obese mice demonstrated that butyrate supplementation at 5% wt/wt in high-fat 
diet prevented development of dietary obesity and insulin resistance (Fig. 7A). 
The change in insulin sensitivity may be a consequence of a reduction in 
adipose tissue levels (Gao et al., 2009; Gobinath et al., 2010). This may suggest 
that butyrate could be an effective compound in the treatment of obesity and 
insulin resistance in obese individuals.  
Furthermore, plasma glucose level could be significantly decreased in diabetic 
rats in response to administration of XOS or FOS. Intake of FOS has been 
reported to decrease fasting blood glucose levels in diabetic subjects and dietary 
supplementation with XOS improved blood sugar and lipids levels in type 2 
diabetes in murine (Fig. 7B) and human models (Luo et al., 2000; Sheu et al., 
2008; Gao et al., 2009). It can be concluded that consumption of FOS- or XOS-
containing diets could be beneficial in relieving severity of hyperglycaemia. 
 
It is well established that elevated plasma LDL-cholesterol 
concentrations can increase risk on heart diseases. Many studies confirm that 
dietary supplementation with LDCs- effectively reduce plasma cholesterol 
levels. The mechanism underlying the cholesterol lowering effects of SCFA 
such as propionate, includes the inhibition of cholesterol synthesizing enzyme 
(3-hydroxy 3-methylglutaryl CoA reductase) and redistribution of cholesterol 
from the blood plasma to the liver (Wright et al., 1990; Arora et al., 2011). 
Propionate can also improve the secretion and synthesis of bile acids, and 
cholesterol 7α hydroxylase activity in primary cultured rat hepatocytes by 
increasing mitochondrial succinyl CoA concentrations (Imaizumi et al., 1992; 
Levrat et al., 1994). Furthermore, addition of propionate and butyrate to Caco-2 
  
 
 
 
 
 
 
 
cell lines trigger downregulation of genes involved in the intestinal cholesterol 
synthesis pathway (Alvaro et al., 2008). 
Carbohydrates such as inulin, resistant starch and l-rhamnose lead to 
increased concentrations of propionate after fermentation, exhibiting 
hypocholesterolemic effects by reduction of serum total cholesterol levels and 
hepatic triglyceride levels both in animals and humans (Trautwein et al., 1998; 
Cheng and Lai, 2000; Vogt et al., 2004).  
Moreover, high LDC intake is associated with lowering blood pressure and 
prevention of cardiovascular diseases (Fernandez, 2001; Yeo et al., 2009). A 
number of mechanisms have been proposed to clarify the action in prevention 
of hypertension and heart diseases. Lowering of blood lipid and cholesterol 
levels, reduction of obesity, reduction of diabetes risk and improving absorption 
of minerals might be important in this respect (Yeo et al., 2009). 
The group of soluble prebiotics to which belongs pectin, konjac mannan, 
guar gum, xanthan gum and modified starches cause a thickening and viscous 
effect in solutions (Levrat-Verny et al., 2000). Those properties are highly 
beneficial in lowering blood cholesterol levels and for increasing satiety. 
Further, insoluble grain fibers can be associated with reduced risk on diabetes, 
because they are fermented to SCFAs which improve hepatic insulin sensitivity 
(Weickert et al., 2006; Yeo et al., 2009). As mentioned previously, prebiotics 
improve the absorption of minerals as calcium which can be associated with a 
reduction of hypertension (Allender et al., 1996; Zemel, 2001). Also inulin has 
been reported to enhance the absorption of calcium in human (Abrams et al., 
2005; Yeo et al., 2009). Prebiotics increase the absorption of calcium mainly 
due to sequestering it in the gastrointestinal tract. When reaching the colon, 
calcium is released from the prebiotic matrix and absorbed in epithelial cells 
(Scholz-Ahrens et al., 2001; Yeo et al., 2009). 
 
Gastrointestinal diseases treatment and prevention 
 
Digestive diseases comprise of many acute and chronic disorders of the 
GI tract ranging from common digestive syndromes as constipation to serious 
and lethal diseases. GI illnesses include functional bowel diseases such as 
irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD) such as 
Crohn's disease (CD) and ulcerative colitis (UC). Many GI disorders can be 
relieved by diet and medications, but a large majority of them are difficult to 
treat by conventional medicine. Symptoms of GI disorders often include 
cramping, abdominal pain, inflammation of the lining of the large and/or small 
intestine, chronic diarrhea, rectal bleeding and weight loss (Leenen and 
Dieleman, 2007). Inflammatory bowel disease represents the clinical outcome 
of three interactive pathogenic factors: genetic susceptibility, environmental 
triggers and immune deregulation (Shanahan, 2004). 
CD can occur at any location in the intestinal tract with diverse symptoms 
involving chronic inflammation of the gastrointestinal tract, non-bloody 
diarrhea, abdominal cramps, fever, weight loss, and perianal manifestations 
(Leenen and Dieleman, 2007). Treatments for CD include pharmaceuticals as 
steroids, 5-aminosalicylic acid, antibiotics, azathioprine/6-mercaptopurine and 
methotrexate (Leenen and Dieleman, 2007). 
  
 
 
 
 
 
 
 
In CD, nucleotide-binding oligomerization domain-containing protein 2 
(NOD2) gene mutations, are allied with decreased transcription of the anti-
inflammatory cytokine interleukin 10 (IL-10). A reduction in IL-10 levels 
contributes to magnification of the granulomatous reaction and lack of 
resolution of inflammation, leading to a pathogenic state (Fava and Danese, 
2010). Furthermore, NOD2 expression is involved in regulation of the gut wall 
colonization by bacteria with higher levels of bacterial colonization in Nod2-
deficient animals and as well in human (Fava and Danese, 2010). The intestinal 
microbiota play a vital role in the inflammation associated with CD disease 
especially including immunoregulatory Bifidobacteria species interacting with 
the mucosal immune system. They induce dendritic cells to produce and release 
high amounts of IL-10 (Hart et al., 2004; Sartor, 2004). Prebiotics such as FOS, 
XOS or inulin, with their capacity to increase fecal and mucosal Bifidobacteria, 
can modulate mucosal dendritic cell (DC) function in patients with CD 
(Lindsay et al., 2006; Leenen and Dieleman, 2007; Hedin et al., 2007). 
Moreover, DCs expressed higher levels of Toll-like receptor 2 (TLR2) and/or 
TLR4 receptors following FOS supplementation. Upregulation of TLR 
expression is a possible result of better recognition of Bifidobacteria by DC and 
signaling via TLRs which is often correlated with initiation of inflammatory 
responses (Hausmann et al., 2000). Nevertheless, recent studies proposed a 
perspective shielding role for TLRs in the gut. TLR activation is indispensable 
for intestinal homeostasis, protection against gut injury and epithelial restitution 
(Hausmann et al., 2000; Rakoff-Nahoum et al., 2004). Although the mechanism 
by which prebiotics regulate expression of TLR expression in DCs remains to 
be determined, their beneficial role in treating inflammatory bowel diseases is 
clear.  
UC is a colon inflammation and involves symptoms as diarrhea, rectal 
bleeding, and abdominal pain, often accompanied by fever and weight loss. 
Pseudopolyps, which are commonly detected during endoscopy of individuals 
with UC, increase the risk on developing colorectal cancer at later stages. 
Medical treatment of UC is vastly related to CD treatment. Prebiotics as inulin, 
oligofructose-enriched inulin and goat milk oligosaccharides are known to 
reduce UC symptoms in murine models (Videla et al., 2001; Hoentjen et al., 
2005; Daddaoua et al., 2006; Lara-Villoslada et al., 2006). Those LDCs inhibit 
the adhesion of bacteria to the epithelial membrane, reduce bacterial 
translocation and promote selective growth of Lactobacilli and Bifidobacteria 
(Videla et al., 2001; Hoentjen et al., 2005; Daddaoua et al., 2006; Lara-
Villoslada et al., 2006). At present LDCs are often recommended as valuable 
alternatives to current therapies to treat IBD. Although inulin-type fructans and 
FOS showed a beneficial role in IBS symptome reduction in many individuals, 
the opposite effects may arise depending on patient sensitivity, supplementation 
periods and doses (Kelly, 2009). For example oligofructoses, inulin and GOS, 
which are able to increase stool weight and relieve constipation, can also 
increase flatulence and bloating (Spiller, 2008; Kelly, 2009). Also 
supplementation with lactulose, one of the best recognized treatments of 
constipation, is not fully beneficial due to production of significant amounts of 
gas and abdominal pain that aggravate symptoms of IBS (Spiller, 2008). 
Compounds that are poorly absorbed in the intestine such as sorbitol, fructose 
  
 
 
 
 
 
 
 
and polyhydric alcohols are used as substrates for bacterial fermentation 
(Fernandez-Bañares et al., 1991; Symons et al., 1992; Spiller, 2008). Due to 
their small molecular weights they trap a considerable amount of water in the 
gut causing unwanted diarrhea in some patients (Fernandez-Bañares et al., 
1991; Symons et al., 1992). As a consequence, the use of prebiotics to treat IBS 
is still uncertain and awaits more trials. 
 
Strategies to increase prebiotics properties 
 
As discussed above, prebiotics are highly important natural compounds 
that could be involved in treatment and prevention of many diseases. The 
improvement of the prebiotic activity is an essential pharmaceutical target and 
follows two main strategies. The first is to seek new molecules with a potential 
superior prebiotic activity. The recent success of the concept of prebiotics and 
functional foods has stimulated researchers to examine, through a screening, the 
possibility of identifying other molecules with similar or even better properties. 
Among the most explored groups are the starch-polysaccharides and â-glucans. 
Supplementation of rodent diets with 1% â-glucans of yeast origin increased 
defenses against Salmonella typhimurium and enhanced the level of fecal 
Lactobacilli and Bifidobacteria (Ho Hoa, 2000). 
Other potential prebiotics are acacia gums. Research demonstrated that, 
after administration of two of these compounds, the levels of SCFAs were 
increased. At the same time an inhibition of Clostridium was recorded, in both 
cases, and an active stimulation of Lactobacilli in one case (Michel et al., 
1998).  
Another improvement strategy is focused on “whole colon” protection. 
Through the use of mixtures containing different types of prebiotics with 
different structural features (DP and branching), one attempts to establish 
fermentation processes along the entire surface of the colon. It is well-known 
that small, linear oligosaccharides are more quickly utilized in the proximal part 
of the colon while, on the contrary, the resistant starch, branched or higher DP 
saccharides are degraded more slowly, at least partially reaching the distal part 
of the colon. For example, the effects of a diet based on wheat bran and 
resistant starch on pigs were studied and indeed, the presence of wheat bran 
caused an increased concentration of butyrate in the distal portion of the colon 
(Govers et al., 1999).  
For the same reasons, attention is shifting from inulin-type fructans to 
the use of alternative type fructans (e.g., wheat graminans and Agave fructans ) 
as promising prebiotics (Huazano-Garcia et al., 2009; Gomez et al., 2009; 
Casiraghi et al., 2011; Jenkins et al., 2011). Finally, some prebiotics seem to 
selectively stimulate probiotic strains. This was recently reported for a 2-
substituted-(1,3)β-D-glucan. Moreover, the presence of this particular glucan 
stimulated the in vitro adhesion of the probiotic Lactobacillus plantarum 
WCFS1 to human intestinal epithelial cells (Russo et al., 2012).  
 
Concluding remarks 
 
  
 
 
 
 
 
 
 
Technological and scientific progress has allowed us to understand the 
underlying mechanisms of diseases, their treatment and prevention. Functional 
foods are important class of molecules which open new perspectives in research 
over cure of many disorders. The basic concept considered and analyzed in this 
review is that the inception of chronic degenerative diseases of gastrointestinal 
tract and other parts of our body might be prevented by the daily application of 
a diet based on specific foods from the beneficial group of prebiotics. The 
profits of prebiotics consumption have been known for a long time, but 
currently the main aim is to focus on their role in the prevention mechanism 
underlying the onset of diseases such as colon cancer, diabetes mellitus, obesity 
and also on the symbiotic interaction among human organism and the microbial 
flora. The extensive evidence presented in this review, based on the work of 
many research groups on animals and human, strongly suggest that prebiotics 
are strong candidates in the area of disease prevention. A diet rich in prebiotics 
has been proven to protect from many illnesses. Therefore, it can be concluded 
that their action is not fiction but reality. However, large scale clinical studies 
are necessary to further corroborate these findings. 
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Figure legends 
 
Figure 1. Functions of the intestinal microflora (A) Changes in the bacterial 
populations in the different parts of the GI tract. (B) Main aerobic and 
anaerobic species found in healthy individuals which exert a combination of 
protective, structural and metabolic effects on the intestinal mucosa (Figures 
from O’Hara et al., 2006).  
 
Figure 2. An overview of plant fructan synthesis starting from sucrose. Inulin-, 
levan-, graminan-, neo-inulin and neo-levan type fructans can be discriminated. 
The following enzymes are involved: sucrose:sucrose 1-fructosyl transferase (1-
SST),  sucrose:fructan 6-fructosyl transferase (6-SFT),  fructan:fructan 6G-
fructosyl transferase (6G-FFT) and  fructan:fructan 1-fructosyl transferase (1-
FFT).  
 
Figure 3. Role of SCFAs as important elements preventing colonization of 
bacterial pathogens. (A) Acetate produced by Bifidobacterium origins 
acidification and prevents colonization by EHEC and also prevents 
translocation of Shiga toxin (Stx2) into the bloodstream. (B) Direct binding of 
acetate to G protein coupled receptors 43 (GPR43) on immune cells regulates 
inflammatory responses. (C) Butyrate prevents infection by up-regulation of 
antimicrobial peptides (Figures adapted from Ashida et al., 2011). 
 
Figure 4. Beneficial effects of short-chain fatty acids on cells in various stages 
of carcinogenesis. But (n-butyrate), Prop (propionate), Ac (acetate) (Figure 
modified from Scheppach et al., 2001).  
 
Figure 5. The role of quercetin in cancer defence. LPO (lactic peroxidase); O2 – 
(superoxide anion); H2O2 (hydrogen peroxide); GSH (glutathione); GS• 
(oxidized GSH); GSSG (glutathione disulfide) (Figure derived from Gibellini et 
al., 2010). 
 
Figure 6. Cellular effects induced by cytoprotective flavonoids. The → 
designates activation or induction, and ⊣ inhibition or blockade. Bcl-2 (B-cell 
lymphoma 2), Bax (Bcl-associated X protein), Caspase-3 (cysteine-aspartic 
protease 3), p53 (tumor protein 53) (Figure modified from Choi et al., 2005). 
 
Figure 7. Treatment of obesity and high glucose levels in mice with use of 
butyrate. Obesity was induced in C57BL/6J mice fed a high-fat diet for 16 
weeks (21 weeks in age). The obese mice were then treated with butyrate 
  
 
 
 
 
 
 
 
through food supplementation for 5 weeks. (A) In control mice increase of body 
weight (BW) has been measured after 5 weeks of fed with a high-fat diet. Mice 
which receive a high-fat diet with 5% wt/wt butyrate reduced weight during 
same treatment time. (B) Fasting glucose levels ware reduced in group treated 
with a high-fat diet with 5% wt/wt butyrate supplementation. Tail vein blood 
was used for glucose assay after 16 h fasting during the period of high-fat diet 
feeding. Values are the means ± SE (n = 8 in each group). *P < 0.05. **P < 
0.001 (n = 2) (Data used from Gao et al., 2009). 
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